Search

everythinglearnresearchcommunity

for

Search:↓

RU58841 and Pyrilutamide (Kx-826) are both topical anti-androgens, but neither is effective for hair regrowth. RU58841 has more anecdotal support, while Pyrilutamide has progressed further in trials, though both have limitations.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

A user received a custom topical treatment for hair loss from Rootsbyga, which includes minoxidil and possibly other ingredients to enhance its effectiveness. The initial test cost $120, and the monthly topical costs around $70, with concerns about long-term use of steroids like hydrocortisone.

Pyrilutamide is believed to be more effective than RU58841 and 1 mg finasteride in treating hair loss, with no systemic hormonal effects and the potential to block more than 31% of scalp DHT. It may also antagonize scalp testosterone due to its action as an androgen receptor antagonist.

The user is considering storing Fluridil in a different container for easier application and asks if it can be mixed with Minoxidil or if hair styling products will affect its potency. They also inquire about the order and timing of applying these hair loss treatments.

OP mixed RU58841 with minoxidil and noticed undissolved particles. They are seeking advice on whether it matters or how to fully dissolve it.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.

The conversation discusses using microneedling with copper peptides, specifically GHK-Cu, for hair loss treatment. Some users combine it with minoxidil and topical finasteride, applying peptides either topically or through injection.

The user is using RU58841, dutasteride, and minoxidil for hair loss, storing RU58841 in the fridge and applying it nightly. They report more baby hairs on the temples but are unsure if it's due to new growth or miniaturization, and seek advice on mixing and results from RU58841.

Combining topical minoxidil and pyrilutamide (KX-826) for hair loss treatment. It is suggested to apply minoxidil first, wait 20 minutes, then apply pyrilutamide for better absorption.

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

A user shared their experience with a second hair transplant by Dr. Gokhan Gur, focusing on the midscalp and crown with 1849 grafts. Their current treatment includes dutasteride, finasteride, oral and topical minoxidil, and Nizoral shampoo.

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

The user is experiencing significant hair shedding after starting RU58841, despite using dutasteride and oral minoxidil for over a year without stabilization. Others suggest continuing the treatment as shedding can be a normal phase, but caution that RU58841 is unpredictable.

RU58841's potential toxicity to cats is uncertain, similar to minoxidil. Caution is advised to prevent accidental exposure to pets.

The user has been using various hair loss treatments, including dutasteride, oral minoxidil, finasteride, RU58841, and dermarolling, but feels they may have lost hair and is considering a hair transplant. They are advised to stick to one treatment for 6-12 months to see results, as frequent changes may hinder progress.

The conversation is about finding reputable clinics in Canada or near the US border that offer DUT mesotherapy for hair loss. The user is seeking recommendations and cost information for these treatments.

The user experienced severe hair shedding despite using oral finasteride, minoxidil, dutasteride, and RU58841, and was diagnosed with Non-Alcoholic Fatty Liver Disease (NAFLD). They are considering switching to topical treatments due to the ineffectiveness of their current regimen.

A naturally occurring sugar, 2-deoxy-D-ribose, may promote hair growth by forming new blood vessels. There is skepticism about its effectiveness and concerns about potential side effects, with some users comparing it to existing treatments like Minoxidil and finasteride.

The user is experiencing increased hair shedding while using finasteride and RU58841, possibly due to changes in application methods. They are considering adding minoxidil and stemoxydine to their regimen to improve results and manage hair greasiness.

The conversation discusses adding either RU58841 or pyrilutamide to a hair loss treatment regimen that already includes oral dutasteride and oral minoxidil. RU58841 is considered the stronger anti-androgen but may have more side effects.

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

User wants to mix finasteride into stemoxydine instead of minoxidil. Seeks stemoxydine brand recommendations for mixing in the UK.

The conversation is about the effectiveness and trustworthiness of Pyrilutamide hair loss treatment sold by Hairlisciously, with concerns about product purity and a request for alternative suppliers. No specific treatments were confirmed to be used by participants.

The conversation is about gathering serum DHT data from individuals taking dutasteride to investigate its efficacy, especially in cases with unexpectedly low DHT reduction. The aim is to explore potential genetic factors affecting drug metabolism.

Dutasteride at 0.5mg blocks 50% of scalp DHT, while higher doses like 1mg and 2.5mg block more, with 2.5mg blocking up to 80%. Some users report better results with lower doses, and there's confusion about the effectiveness of different dosages on scalp versus serum DHT.

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

The user experienced worsening hair loss despite using dutasteride tablets and is considering switching to dutasteride gel capsules due to concerns about tablet bioavailability. Another user mentioned that countries like Japan, Korea, and India use the tablet form, suggesting the form may not be the issue.

Kintor is producing a cosmetic with KX826, starting at 0.5% concentration and moving to 1%. The 0.5% concentration wasn't as effective as minoxidil and finasteride, but the 1% concentration shows promise.